Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Safety and Effectiveness of AZD0486 Alone or with Other Drugs for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, or Large B-Cell Lymphoma

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying certain blood cancers, specifically Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, and Large B-Cell Lymphoma. The trial will evaluate the safety and effectiveness of a new treatment called AZD0486, which is a type of medication known as a monoclonal antibody. This treatment can be used alone or in combination with other cancer-fighting drugs such as Doxorubicin, Rituximab, Prednisolone, Cyclophosphamide, Vinorelbine, and Acalabrutinib.

The purpose of the study is to determine how safe and tolerable AZD0486 is when given to patients with these types of blood cancers. The study will also find the best dose to use in future research. Participants will receive the treatment either through an infusion into a vein or an injection under the skin. The study will be conducted in several phases, starting with a smaller group of participants to assess safety, and then expanding to include more participants to further evaluate the treatment's effectiveness.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. The trial aims to provide valuable information on how well AZD0486 works in treating these blood cancers and to ensure that it is safe for patients. The study is expected to continue until 2026, with recruitment starting in 2025.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment phase

    The initial treatment phase involves the administration of AZD0486, a human igg4 kappa monoclonal antibody against cd3 and cd19. This medication is given as a solution for infusion, which means it is administered directly into the bloodstream through a vein.

    During this phase, the patient may also receive rituximab and doxorubicin hydrochloride, both administered intravenously. These medications are part of the treatment regimen for certain blood cancers.

  2. Step 2

    Combination therapy phase

    In the combination therapy phase, AZD0486 may be used alongside other anticancer agents. These include acalabrutinib, which is taken orally as a 100 mg film-coated tablet, and cyclophosphamide, administered intravenously.

    Additional medications such as vinorelbine and betamethasone sodium phosphate may also be included in the treatment plan, depending on the specific requirements of the patient's condition.

  3. Step 3

    Maintenance phase

    The maintenance phase focuses on sustaining the treatment's effectiveness. Prednisolone is taken orally to help manage inflammation and other symptoms associated with the condition.

    Regular monitoring of the patient's response to the treatment is conducted to ensure the best possible outcomes.

  4. Step 4

    Follow-up and monitoring

    Throughout the trial, the patient's health is closely monitored. This includes regular assessments of vital signs, laboratory tests, and evaluations of any side effects experienced.

    The trial aims to assess the safety and tolerability of the treatment, as well as to determine the recommended dose for future studies.

Who can join the trial?

20 criteria

  • Must be over 18 years old.
  • For Sub-study 2: Must have a diagnosis of Mantle Cell Lymphoma (MCL) according to the World Health Organization (WHO).
  • For Sub-study 2: Must be in Stage II, III, or IV according to the Ann Arbor classification, which is a way to describe the extent of lymphoma.
  • For Sub-study 2: Must have at least one measurable site of disease as per the Lugano classification, which is a method to assess lymphoma.
  • For Sub-study 2: Must have an Absolute Lymphocyte Count (ALC) of less than 10,000. Lymphocytes are a type of white blood cell.
  • For Sub-study 2, Cohort 2A: Must have experienced a relapse after two or more lines of therapy, including treatment with a BTK inhibitor (BTKi), which is a type of medication.
  • For Sub-study 2, Cohort 2B: Must have experienced a relapse or progression after one or more lines of therapy, not including a BTKi.
  • For Sub-study 3: Must have Large B-cell lymphoma according to WHO 2022 or have relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) after at least one prior line of therapy.
  • For Sub-study 3: Must have an International Prognostic Index (IPI) score of 2-5, which helps predict the outcome of lymphoma.
  • For Sub-study 3: Must have at least one measurable site of disease as per the Lugano classification.
  • For Sub-study 3: Must have a Left Ventricular Ejection Fraction (LVEF) greater than 50%. LVEF is a measure of how well the heart pumps blood.
  • For all sub-studies: Must have an ECOG performance status of 0 to 2, which is a scale to assess how a disease affects daily living abilities.
  • For Sub-study 3: Must use contraception for at least 12 months after the last dose of R-CHOP (a chemotherapy regimen) or 6 months after the last dose of AZD0486.
  • For all sub-studies: Must use contraception during treatment and for at least 6 months after the final dose.
  • For all sub-studies: Must have confirmed CD19 expression if previously treated with anti-CD19 therapy. CD19 is a protein found on the surface of certain cells.
  • For Sub-study 1: Must have a diagnosis of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) and meet the iwCLL criteria for treatment, which are guidelines for treating CLL.
  • For Sub-study 1: For SLL, must have at least one measurable site of disease as per the Lugano classification.
  • For Sub-study 1: Must have an absolute lymphocyte count of less than 10,000.
  • For Sub-study 1, Cohort 1A: Must have had at least two prior lines of therapy, including treatment with a BTKi and a BCL2 inhibitor (BCL2i), which are types of medications.
  • For Sub-study 1, Cohort 1B: Must have had at least one prior line of therapy and be sensitive to or not previously treated with a BTKi.

Who cannot join the trial?

4 criteria

  • Patients with medical conditions other than Large B-Cell Lymphoma, Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, or Mantle Cell Lymphoma cannot participate.
  • Individuals who are not within the specified age range for the study are excluded. The age range is not specified here, but it is important for eligibility.
  • Participants who are part of a vulnerable population, which means groups that may need special protection, are not eligible.
  • Both male and female participants are considered, so gender is not an exclusion factor.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

AZD0486 is an investigational medication being studied for its potential to treat certain types of blood cancers known as mature B-cell malignancies. This includes conditions like Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, and Large B-Cell Lymphoma. The medication is being tested both on its own and in combination with other cancer treatments to evaluate its safety and effectiveness. The study aims to find the best dose for future research.

What is already known about the treatment

AZD0486 – This medication is administered either intravenously (IV) or subcutaneously (SC) and is currently being evaluated in clinical trials for its safety and effectiveness in treating mature B-cell malignancies, such as Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma. It is in the investigational stage, with ongoing studies to determine the optimal dosage for further phases. AZD0486 is primarily indicated for these types of cancers and works by targeting specific pathways involved in the growth and survival of cancer cells. It belongs to the pharmacological class of anticancer agents, specifically designed to interfere with cancer cell proliferation.

Investigated diseases

  • Large B-Cell Lymphoma

    This is a type of non-Hodgkin lymphoma that originates in the B cells, which are a type of white blood cell. It typically presents as a rapidly growing mass, often in the lymph nodes, spleen, liver, or other organs. The disease can spread to other parts of the body, including the bone marrow and central nervous system. Symptoms may include swollen lymph nodes, fever, night sweats, and weight loss.

  • Chronic Lymphocytic Leukemia

    This is a slow-growing cancer of the blood and bone marrow that primarily affects older adults. It involves the production of too many abnormal lymphocytes, a type of white blood cell. Over time, these abnormal cells can crowd out healthy blood cells, leading to symptoms such as fatigue, infections, and swollen lymph nodes. The disease often progresses slowly, and some individuals may not experience symptoms for years.

  • Small Lymphocytic Lymphoma

    This is a type of non-Hodgkin lymphoma that is closely related to chronic lymphocytic leukemia. It primarily affects the lymph nodes and is characterized by the accumulation of small, mature lymphocytes. The disease progresses slowly and may present with symptoms such as painless swelling of lymph nodes, fatigue, and night sweats. It is considered the same disease as chronic lymphocytic leukemia but with a different primary location.

  • Mantle Cell Lymphoma

    This is a rare type of non-Hodgkin lymphoma that arises from B cells located in the "mantle zone" of the lymph node. It is characterized by the overproduction of abnormal B cells, which can spread to other parts of the body, including the bone marrow and gastrointestinal tract. Symptoms may include swollen lymph nodes, fever, night sweats, and weight loss. The disease is typically aggressive and can progress rapidly.

Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2024-515034-33-00Protocol codeD7407C00001Estimated enrolment446 patientsSponsorAstraZeneca AB

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.